PT  - JOURNAL ARTICLE
AU  - SJO. Veldhuyzen van Zanten
AU  - P. M. Sherman
AU  - R. H. Hunt
TI  - Helicobacter pylori: new developments and treatments
DP  - 1997 Jun 01
TA  - Canadian Medical Association Journal
PG  - 1565--1574
VI  - 156
IP  - 11
4099  - http://www.cmaj.ca/content/156/11/1565.short
4100  - http://www.cmaj.ca/content/156/11/1565.full
SO  - CMAJ1997 Jun 01; 156
AB  - The authors highlight new developments in research on Helicobacter pylori. There is now consensus that all patients with newly diagnosed or recurrent duodenal or gastric ulcers who have a positive test result for H. pylori should be treated for the infection. Patients presenting with complications of ulcers, such as bleeding, should also be treated. H. pylori has recently been classified as a definite human carcinogen by the International Agency for Research on Cancer. In treatment, new combination regimens, consisting of 3 or 4 different drugs, cure the infection in more than 80% of patients. Currently, the best combinations are: (1) omeprazole (or another proton-pump inhibitor), clarithromycin and metronidazole, (2) omeprazole (or another proton-pump inhibitor), clarithromycin and amoxicillin, (3) bismuth subsalicylate, tetracycline and metronidazole, and (4) omeprazole, bismuth subsalicylate, tetracycline and metronidazole.